RxDoctor Payments Data

Grace Huang, MD

Ophthalmology · Philadelphia, PANPI 1649666561

Payments from drug & device makers

$2,588in general payments, 2019–2025

Across 50 payments — averaging $51.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$837
  • Glaukos Corporation$329
  • Dompe US, Inc.$318
  • Biotissue Holdings Inc.$187
  • Cook Medical LLC$186
  • Eyevance Pharmaceuticals LLC$168
  • plus $563 from 13 others

What the payments were for

  • Food & beverage$2,588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,588 in reported general payments places this provider in the 60th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$232,792
Medicare patients
600
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$39,090
LumiganBimatoprost66$31,920
XiidraLifitegrast26$21,546
Cyclosporine54$14,586
Prednisolone Acetate340$11,292
Brimonidine Tartrate84$6,597
Latanoprost637$5,641
SimbrinzaBrinzolamide/Brimonidine Tart26$5,627
Brinzolamide13$5,093
XalatanLatanoprost18$4,427
Dorzolamide-TimololDorzolamide/Timolol/Pf36$4,058
RhopressaNetarsudil Mesylate11$3,638
TobradexTobramycin/Dexamethasone13$3,429
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$3,215
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$3,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$98$71,010126 claims
AlconSimbrinza$837$5,62726 claims
PfizerXalatan$29$4,42718 claims
Aerie Pharmaceuticals, Inc.Rhopressa$15$3,63811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →